Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Pancreatic Adenocarcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Pancreatic Cancer (499)

Pancreatic Ductal Adenocarcinoma (133)

Pancreatic Cancer (499)

Pancreatic Ductal Adenocarcinoma (133)

›

No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval 5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive : A1	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval 5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive : A1
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
NTRK3 fusion	Pancreatic Adenocarcinoma	NTRK3 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Pancreatic Adenocarcinoma	NTRK2 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Pancreatic Adenocarcinoma	NTRK1 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Pancreatic Adenocarcinoma	NTRK3 fusion	Pancreatic Adenocarcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	5-fluorouracil + capecitabine Sensitive: A2 - Guideline 5-fluorouracil + capecitabine Sensitive : A2	5-fluorouracil + capecitabine Sensitive: A2 - Guideline 5-fluorouracil + capecitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2